| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
|
Compstatin is a novel and potent 13-residue cyclic peptide acting as a potent inhibitor of the complement system C3 with species specificity. Compstatin binds to baboon C3 and is resistant to proteolytic cleavage in baboon blood (similar to humans).
| ln Vitro |
Comprestatin in human blood has an in vitro half-life of roughly two hours [2]. Comprestatin creates pearl clusters in solution when it rotates β on the Gln-5-Gly-8 residue with the disulfide bridge Cys-2-Cys12, residues Ile-1-Val-4 and Thr-13 [3].
|
|---|---|
| ln Vivo |
When compstatin (21 mg/kg) was administered as a combination bolus and infusion medication, total suppression was seen. Compstatin fully prevents heart rate, systemic, central, and pulmonary arterial pressure from being negatively impacted by heparin/protamine-induced complement activation in vivo [1]. In baboons smoking, paroxetine remains constant for almost twenty-four hours [1]. Pig xenografts in the comprestatin-infused group had a substantially longer transitory period than those in the saline group [2].
|
| Animal Protocol |
Animal/Disease Models: Juvenile baboons (P. Anubis) weigh 10.5-28.8 kg [1].
Doses: 50, 25 mg/kg, 60 minutes after heparin injection, 2 minutes before protamine injection. Route of Administration: Push Note. Experimental Results: Complete inhibition of complement activation induced by heparin-protamine complex. |
| References |
[1]. Soulika AM, et al. Inhibition of heparin/protamine complex-induced complement activation by Compstatin in baboons. Clin Immunol. 2000 Sep;96(3):212-21.
[2]. Fiane AE, et al. Compstatin, a peptide inhibitor of C3, prolongs survival of ex vivo perfused pig xenografts. Xenotransplantation. 1999 Feb;6(1):52-65. [3]. Bert J C Janssen, et al. Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition. J Biol Chem. 2007 Oct 5;282(40):29241-7. [4]. A Sahu, et al. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. J Immunol. 1996 Jul 15;157(2):884-91. |
| Molecular Formula |
C66H99N23O17S2
|
|---|---|
| Molecular Weight |
1550.7662
|
| CAS # |
206645-99-0
|
| Related CAS # |
Compstatin TFA
|
| SMILES |
C([C@H]1C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CSSC[C@@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N1)=O)CC(=O)O)=O)CCC(=O)N)=O)C(C)C)=O)C(C)C)=O)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@H](C(=O)N)[C@H](O)C)=O)CCCNC(N)=N)=O)CC1NC=NC=1)=O)CC1NC=NC=1)=O)=O)C1=CNC2=CC=CC=C12
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~64.48 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (64.48 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.6448 mL | 3.2242 mL | 6.4484 mL | |
| 5 mM | 0.1290 mL | 0.6448 mL | 1.2897 mL | |
| 10 mM | 0.0645 mL | 0.3224 mL | 0.6448 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
